Neutrolis Announces Positive First-in-Human Phase 1a Results from LIBERATE-I Trial of NTR-1011, a First-in-Class DNASE1L3 Fusion Protein

Key Takeaways:

• Neutrolis unveiled encouraging Phase 1a findings for its LIBERATE-I trial (NCT07237659).
• NTR-1011 is a first-in-class DNASE1L3 fusion protein that dismantles pathogenic NETs.
• The therapy is designed to lower inflammation without immunosuppression.
• This marks an important milestone in exploring treatments for autoimmune disease.

Background

Neutrolis, Inc., a clinical-stage biotechnology company based in Cambridge, Massachusetts, has announced promising first-in-human Phase 1a results for its LIBERATE-I trial (NCT07237659). The trial centers on NTR-1011, a first-in-class DNASE1L3 fusion protein intended to dismantle pathogenic Neutrophil Extracellular Traps (NETs).

Company Focus

Founded on the principle of delivering rapid-acting, non-immunosuppressive therapies, Neutrolis targets NETs to help reduce inflammatory responses. By directing treatments at these specific immune complexes, the company seeks to address autoimmune diseases at a fundamental level rather than broadly suppressing the immune system.

Mechanism of Action

NTR-1011 is specifically engineered to break down NETs. NETs, which can trigger excessive inflammation, are often implicated in autoimmune conditions. According to Neutrolis, this disruption of NETs is designed “to prevent their downstream proinflammatory effects that drive immune activation in autoimmune disease.”

Phase 1a Trial Highlights

The LIBERATE-I trial’s Phase 1a portion evaluated the initial safety and tolerability profile of NTR-1011 in humans. Preliminary topline data show positive results, indicating that the DNASE1L3 fusion protein’s mechanism may offer a novel route to controlling inflammation without inhibiting healthy immune function.

Significance in Autoimmune Research

Current approaches to autoimmune disease often rely on agents that suppress the immune system entirely. In contrast, NTR-1011 focuses on neutralizing a harmful driver of inflammation while leaving other immune defenses intact. This approach could represent a step forward in mitigating serious autoimmune issues with fewer side effects.

Looking Ahead

This early success in Phase 1a sets the stage for further trials, where Neutrolis plans to explore both efficacy and broader safety measures. As interest grows in targeted autoimmune therapies, researchers and clinicians await more detailed results from future trial phases to confirm the clinical potential of NTR-1011.